Pharmaceuticals, Biotechnology and Life Sciences
ImaginAb has enrolled its first patient for the Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at City of Hope in Los Angeles County.
Eli Lilly’s Cyramza got its fifth FDA approval for in an advanced or metastatic cancer – this one for the second-line treatment of patients with hepatocellular carcinoma (HCC) who are AFP-High (AFP ≥400 ng/mL).
Swedish Medivir said Monday that positive data from the investigator-initiated study of remetinostat in basal cell carcinoma (BCC) patients has shown that remetinostat gel offers a potentially effective and well-tolerated, non-surgical intervention for treatment of localized BCCs.
59 percent complete response rate in a subset of patients withendoscopically unresectable low-grade upper tract urothelial cancer(UTUC).
Approval based on data showing Kadcyla cut the risk of diseaserecurring by half compared to Herceptin in the adjuvant setting forspecific patients with HER2-positive early breast cancer
Seed will enable growth of the PolyProx team and furtherdevelop our technology over the next two years
The safety profile of KEYTRUDA was consistent with thatpreviously observed in gastric cancer
Winther trial shows RNA profiling togetherwith DNA testing matches more patients with advanced cancer topersonalized therapies than DNA profiling for tumor mutations alone.
Global Markets to 2023 with Abbott Laboratories, Bayer Healthcare, GlaxoSmithKline, Merck & Co, Pfizer and Sanofi at the Forefront
LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, has expanded two additional cohorts from the Phase II SUMMIT…